Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PolyPid ( (PYPD) ) has shared an announcement.
On June 16, 2025, PolyPid Ltd. announced it secured $26.7 million through the exercise of warrants following the successful results of its Phase 3 SHIELD II trial for D-PLEX100, which showed a significant reduction in surgical site infections. This funding is expected to extend the company’s financial runway beyond the anticipated FDA approval of D-PLEX100. The proceeds will be used for a New Drug Application submission, launch preparations, and general corporate purposes, potentially enhancing PolyPid’s market positioning and operational capabilities.
The most recent analyst rating on (PYPD) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. is a late-stage biopharmaceutical company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology enables the controlled, prolonged release of therapeutics directly at the surgical site. PolyPid’s lead product candidate, D-PLEX100, has demonstrated significant efficacy in reducing surgical site infections in Phase 3 clinical trials. The company is also exploring the use of its technology in oncology with its OncoPLEX program.
Average Trading Volume: 425,410
Technical Sentiment Signal: Sell
Current Market Cap: $37.4M
See more insights into PYPD stock on TipRanks’ Stock Analysis page.